Insider Selling: ICU Medical, Incorporated (NASDAQ:ICUI) Director Sells 20,000 Shares of Stock
ICU Medical, Incorporated (NASDAQ:ICUI) Director George A. Lopez sold 20,000 shares of the firm’s stock in a transaction that occurred on Tuesday, December 3rd. The stock was sold at an average price of $184.29, for a total transaction of $3,685,800.00. Following the completion of the transaction, the director now directly owns 368,864 shares of the company’s stock, valued at $67,977,946.56. The transaction was disclosed in a document filed with the SEC, which is available at the SEC website.
ICUI stock opened at $184.73 on Wednesday. The stock has a 50-day simple moving average of $170.69 and a two-hundred day simple moving average of $196.98. ICU Medical, Incorporated has a twelve month low of $148.89 and a twelve month high of $259.72. The firm has a market capitalization of $3.88 billion, a PE ratio of 25.27 and a beta of 0.92.
ICU Medical (NASDAQ:ICUI) last announced its quarterly earnings results on Monday, November 11th. The medical instruments supplier reported $1.65 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $1.62 by $0.03. ICU Medical had a net margin of 5.66% and a return on equity of 12.13%. The firm had revenue of $307.47 million for the quarter, compared to the consensus estimate of $297.83 million. During the same period in the prior year, the firm posted $1.85 earnings per share. The company’s revenue for the quarter was down 6.0% on a year-over-year basis. As a group, sell-side analysts expect that ICU Medical, Incorporated will post 7.1 EPS for the current fiscal year.
A number of brokerages have issued reports on ICUI. BidaskClub raised shares of ICU Medical from a “hold” rating to a “buy” rating in a report on Thursday, November 21st. ValuEngine upgraded ICU Medical from a “hold” rating to a “buy” rating in a research report on Tuesday, November 19th. Raymond James raised their price target on ICU Medical from $185.00 to $203.00 and gave the stock a “positive” rating in a report on Tuesday, November 12th. Zacks Investment Research cut ICU Medical from a “hold” rating to a “sell” rating in a research report on Wednesday, August 14th. Finally, TheStreet lowered ICU Medical from a “b-” rating to a “c+” rating in a research note on Monday, August 12th. One investment analyst has rated the stock with a sell rating and three have issued a buy rating to the stock. ICU Medical presently has an average rating of “Buy” and a consensus price target of $242.00.
ICU Medical Company Profile
ICU Medical, Inc develops, manufactures, and sells medical devices used in vascular therapy, critical care, and oncology applications worldwide. It offers infusion therapy products comprising a tube running from a bottle or plastic bag containing a solution to a catheter inserted in a patient's vein.
Further Reading: Balanced Fund
Receive News & Ratings for ICU Medical Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ICU Medical and related companies with MarketBeat.com's FREE daily email newsletter.